Compare MSD & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSD | NERV |
|---|---|---|
| Founded | 1993 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.9M | 166.4M |
| IPO Year | N/A | 2014 |
| Metric | MSD | NERV |
|---|---|---|
| Price | $6.91 | $3.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 56.4K | ★ 131.7K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 11.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.91 | $2.06 |
| 52 Week High | $7.94 | $12.46 |
| Indicator | MSD | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 37.46 | 40.25 |
| Support Level | $6.91 | N/A |
| Resistance Level | $7.44 | $4.73 |
| Average True Range (ATR) | 0.07 | 0.27 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 16.40 | 25.55 |
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.